Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of xionolone plus chemotherapy in platinum-resistant/refractory recurrent ovarian cancer
CTR20190609Phase 2Completed
- Sponsor
- Chipscreen Biosciences
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of chiauranib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Chipscreen Biosciences. Started Apr 2019; status: completed.
02
Drugs
chiauranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20190609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190609.